VectivBio Revenue and Competitors
Estimated Revenue & Valuation
- VectivBio's estimated annual revenue is currently $8.5M per year.
- VectivBio's estimated revenue per employee is $116,781
- VectivBio's current valuation is $175.7M. (January 2022)
Employee Data
- VectivBio has 73 Employees.
- VectivBio grew their employee count by -16% last year.
VectivBio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder and CEO | Reveal Email/Phone |
2 | SVP, Global Medical Affairs and Patient Partnership | Reveal Email/Phone |
3 | VP, Head Clinical Development | Reveal Email/Phone |
4 | VP, Head Corporate Quality and Compliance | Reveal Email/Phone |
5 | VP Regulatory Affairs | Reveal Email/Phone |
6 | VP, Finance | Reveal Email/Phone |
7 | VP Life Cycle Leadership | Reveal Email/Phone |
8 | SVP & Head Human Resources | Reveal Email/Phone |
9 | Executive Director, Patient Support Services, Reimbursement, and Distribution | Reveal Email/Phone |
10 | Chief Legal Officer & Chief Business Officer (from January 2023) | Reveal Email/Phone |
VectivBio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is VectivBio?
VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer, Inc., for its program in achondroplasia, with the ambition to continue to have an impact on people's lives by bringing transformational medicines to patients with serious rare conditions. The company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in R&D, commercialization and business development for innovative products targeting orphan conditions with major unmet medical need. The company is drawing on the expertise of its founders as it continues to build a portfolio of rare disease medicines while advancing its lead program for Short Bowel Syndrome.
keywords:N/A
N/A
Total Funding
73
Number of Employees
$8.5M
Revenue (est)
-16%
Employee Growth %
$175.7M
Valuation
N/A
Accelerator
VectivBio News
BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical...
BASEL, Switzerland, April 07, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical...
VectivBio (Nasdaq: VECT) is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with...
Other Companies in Basel
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $14.5M | 73 | 28% | N/A |
#2 | N/A | 73 | 1% | N/A |
#3 | $35M | 74 | 1% | N/A |
#4 | $35M | 76 | -11% | N/A |
#5 | $12.1M | 78 | 42% | N/A |